HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Research | Clinical Cancer Research |
Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 6, Issue 10 1251-1259, Copyright © 1995 by American Association of Cancer Research
ARTICLES |
SK Batra, S Castelino-Prabhu, CJ Wikstrand, X Zhu, PA Humphrey, HS Friedman and DD Bigner
Duke University Medical Center, Durham, North Carolina 27710, USA.
The type III deletion-mutant gene for the epidermal growth factor receptor (EGFRvIII) is frequently expressed in glioblastomas and in breast and non-small cell lung carcinomas. To understand its contribution to the malignant phenotype in humans, we transfected NR6 cells with the mammalian vector pH beta APr-1-neo containing cDNA for either EGFRvIII or wild-type EGFR. Western blot analyses showed that NR6 transfected with wild-type EGFR (NR6W) contained a normal-sized protein (170 kilodaltons); cells transfected with EGFRvIII (NR6M) contained a truncated protein (145 kilodaltons). NR6W cells demonstrated a saturation binding curve with 125I-labeled EGF (affinity, 1.8 x 10(8); r2 = 0.96). NR6M cells, however, showed a low but consistent level of 125I-labeled EGF binding (affinity, 4 x 10(7); r2 = 0.99) compared with NR6, which lacked binding. The population doubling time was shorter for NR6M (0.64 days) than for NR6W (1.1 days) and NR6V (2.27 days). Soft agar focus formation assay by NR6M was 4- to 5-fold higher than that by NR6W. In nude mice, NR6M (1 x 10(7) cells), without exogenous ligand, formed tumors within 12 days; no tumors were observed over 90 days in mice receiving identical doses of NR6W, NR6V, or NR6 cells. EGF stimulated autophosphorylation of receptor in NR6W (4- to 9-fold) but caused only slight (1.8- to 1.9-fold) to no enhancement in NR6M. Further, there was no difference in constitutive tyrosine kinase activity between NR6M and NR6W. Our results clearly indicate that EGFRvIII functions as an oncoprotein, but its intrinsic tyrosine kinase activity may not be responsible for its biological function.
This article has been cited by other articles:
![]() |
![]() |
![]() |
![]() |
![]() ![]() D. A. Reardon, A. Desjardins, J. J. Vredenburgh, D. M. O'Rourke, D. D. Tran, K. L. Fink, L. B. Nabors, G. Li, D. A. Bota, R. V. Lukas, et al. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial Clin. Cancer Res., April 1, 2020; 26(7): 1586 - 1594. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() A. Roos, H. D. Dhruv, S. Peng, L. J. Inge, S. Tuncali, M. Pineda, N. Millard, Z. Mayo, J. M. Eschbacher, J. C. Loftus, et al. EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival Mol. Cancer Res., July 1, 2018; 16(7): 1185 - 1195. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() A. L. Hein, P. Seshacharyulu, S. Rachagani, Y. M. Sheinin, M. M. Ouellette, M. P. Ponnusamy, M. C. Mumby, S. K. Batra, and Y. Yan PR55{alpha} Subunit of Protein Phosphatase 2A Supports the Tumorigenic and Metastatic Potential of Pancreatic Cancer Cells by Sustaining Hyperactive Oncogenic Signaling Cancer Res., April 15, 2016; 76(8): 2243 - 2253. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() V. C. Saunders, M. Lafitte, I. Adrados, V. Quereda, D. Feurstein, Y. Ling, M. Fallahi, L. H. Rosenberg, and D. R. Duckett Identification of an EGFRvIII-JNK2-HGF/c-Met-Signaling Axis Required for Intercellular Crosstalk and Glioblastoma Multiforme Cell Invasion Mol. Pharmacol., December 1, 2015; 88(6): 962 - 969. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() E. B. Reilly, A. C. Phillips, F. G. Buchanan, G. Kingsbury, Y. Zhang, J. A. Meulbroek, T. B. Cole, P. J. DeVries, H. D. Falls, C. Beam, et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody Mol. Cancer Ther., May 1, 2015; 14(5): 1141 - 1151. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() V. Chandramohan, X. Bao, S. T. Keir, C. N. Pegram, S. E. Szafranski, H. Piao, C. J. Wikstrand, R. E. McLendon, C.-T. Kuan, I. H. Pastan, et al. Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy Clin. Cancer Res., September 1, 2013; 19(17): 4717 - 4727. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() H. Johnson, A. M. Del Rosario, B. D. Bryson, M. A. Schroeder, J. N. Sarkaria, and F. M. White Molecular Characterization of EGFR and EGFRvIII Signaling Networks in Human Glioblastoma Tumor Xenografts Mol. Cell. Proteomics, December 1, 2012; 11(12): 1724 - 1740. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() S. E. Wheeler, E. M. Morariu, J. S. Bednash, C. G. Otte, R. R. Seethala, S. I. Chiosea, and J. R. Grandis Lyn Kinase Mediates Cell Motility and Tumor Growth in EGFRvIII-Expressing Head and Neck Cancer Clin. Cancer Res., May 15, 2012; 18(10): 2850 - 2860. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() I. Vivanco, H. I. Robins, D. Rohle, C. Campos, C. Grommes, P. L. Nghiemphu, S. Kubek, B. Oldrini, M. G. Chheda, N. Yannuzzi, et al. Differential Sensitivity of Glioma- versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors Cancer Discovery, May 1, 2012; 2(5): 458 - 471. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() C. Mascaux, M. W. Wynes, Y. Kato, C. Tran, B. R. Asuncion, J. M. Zhao, M. Gustavson, J. Ranger-Moore, F. Gaire, J. Matsubayashi, et al. EGFR Protein Expression in Non-Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor--A Novel Antibody for Immunohistochemistry or AQUA Technology Clin. Cancer Res., December 15, 2011; 17(24): 7796 - 7807. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() U. H. Weidle, D. Maisel, S. Klostermann, E. H. Weiss, and M. Schmitt Differential Splicing Generates New Transmembrane Receptor and Extracellular Matrix-related Targets for Antibody-based Therapy of Cancer Cancer Genomics Proteomics, September 1, 2011; 8(5): 211 - 226. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() J. H. Sampson, A. B. Heimberger, G. E. Archer, K. D. Aldape, A. H. Friedman, H. S. Friedman, M. R. Gilbert, J. E. Herndon II, R. E. McLendon, D. A. Mitchell, et al. Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma J. Clin. Oncol., November 1, 2010; 28(31): 4722 - 4729. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() J. H. Sampson, G. E. Archer, D. A. Mitchell, A. B. Heimberger, J. E. Herndon II, D. Lally-Goss, S. McGehee-Norman, A. Paolino, D. A. Reardon, A. H. Friedman, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme Mol. Cancer Ther., October 1, 2009; 8(10): 2773 - 2779. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() G. Karpel-Massler, U. Schmidt, A. Unterberg, and M.-E. Halatsch Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand? Mol. Cancer Res., July 1, 2009; 7(7): 1000 - 1012. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() T. Okamura, S. Singh, J. Buolamwini, T. Haystead, H. Friedman, D. Bigner, and F. Ali-Osman Tyrosine Phosphorylation of the Human Glutathione S-Transferase P1 by Epidermal Growth Factor Receptor J. Biol. Chem., June 19, 2009; 284(25): 16979 - 16989. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() F. G. Pernas, C. T. Allen, M. E. Winters, B. Yan, J. Friedman, B. Dabir, K. Saigal, G. S. Mundinger, X. Xu, J. C. Morris, et al. Proteomic Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways Correspond to Gefitinib Sensitivity in Head and Neck Cancer Clin. Cancer Res., April 1, 2009; 15(7): 2361 - 2372. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() J. E. Duex and A. Sorkin RNA Interference Screen Identifies Usp18 as a Regulator of Epidermal Growth Factor Receptor Synthesis Mol. Biol. Cell, March 15, 2009; 20(6): 1833 - 1844. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() J. A. Fromm, S. A. S. Johnson, and D. L. Johnson Epidermal Growth Factor Receptor 1 (EGFR1) and Its Variant EGFRvIII Regulate TATA-Binding Protein Expression through Distinct Pathways Mol. Cell. Biol., October 15, 2008; 28(20): 6483 - 6495. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() E. Arwert, S. Hingtgen, J.-L. Figueiredo, H. Bergquist, U. Mahmood, R. Weissleder, and K. Shah Visualizing the Dynamics of EGFR Activity and Antiglioma Therapies In vivo Cancer Res., August 1, 2007; 67(15): 7335 - 7342. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() S. B. Gendreau, R. Ventura, P. Keast, A. D. Laird, F. M. Yakes, W. Zhang, F. Bentzien, B. Cancilla, J. Lutman, F. Chu, et al. Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647 Clin. Cancer Res., June 15, 2007; 13(12): 3713 - 3723. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() J. C. Sok, F. M. Coppelli, S. M. Thomas, M. N. Lango, S. Xi, J. L. Hunt, M. L. Freilino, M. W. Graner, C. J. Wikstrand, D. D. Bigner, et al. Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting Clin. Cancer Res., September 1, 2006; 12(17): 5064 - 5073. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() K. N. Blehm, P. E. Spiess, J. E. Bondaruk, M. E. Dujka, G. J. Villares, Y.-j. Zhao, O. Bogler, K. D. Aldape, H. B. Grossman, L. Adam, et al. Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy Clin. Cancer Res., August 1, 2006; 12(15): 4671 - 4677. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() D. B. Ramnarain, S. Park, D. Y. Lee, K. J. Hatanpaa, S. O. Scoggin, H. Otu, T. A. Libermann, J. M. Raisanen, R. Ashfaq, E. T. Wong, et al. Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells Cancer Res., January 15, 2006; 66(2): 867 - 874. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() R. K. Goudar, Q. Shi, M. D. Hjelmeland, S. T. Keir, R. E. McLendon, C. J. Wikstrand, E. D. Reese, C. A. Conrad, P. Traxler, H. A. Lane, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition Mol. Cancer Ther., January 1, 2005; 4(1): 101 - 112. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() W. Yang, R. F. Barth, G. Wu, M. J. Ciesielski, R. A. Fenstermaker, B. A. Moffat, B. D. Ross, and C. J. Wikstrand Development of a Syngeneic Rat Brain Tumor Model Expressing EGFRvIII and Its Use for Molecular Targeting Studies with Monoclonal Antibody L8A4 Clin. Cancer Res., January 1, 2005; 11(1): 341 - 350. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() Y. Zhan and D. M. O'Rourke SHP-2-Dependent Mitogen-Activated Protein Kinase Activation Regulates EGFRvIII but not Wild-Type Epidermal Growth Factor Receptor Phosphorylation and Glioblastoma Cell Survival Cancer Res., November 15, 2004; 64(22): 8292 - 8298. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() E. Purev, D. Cai, E. Miller, R. Swoboda, T. Mayer, A. Klein-Szanto, F. M. Marincola, R. Mick, L. Otvos, W. Wunner, et al. Immune Responses of Breast Cancer Patients to Mutated Epidermal Growth Factor Receptor (EGF-RvIII, {Delta}EGF-R, and de2-7 EGF-R) J. Immunol., November 15, 2004; 173(10): 6472 - 6480. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() G. Lammering, T. H. Hewit, M. Holmes, K. Valerie, W. Hawkins, P.-S. Lin, R. B. Mikkelsen, and R. K. Schmidt-Ullrich Inhibition of the Type III Epidermal Growth Factor Receptor Variant Mutant Receptor by Dominant-Negative EGFR-CD533 Enhances Malignant Glioma Cell Radiosensitivity Clin. Cancer Res., October 1, 2004; 10(19): 6732 - 6743. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() C. A. Learn, T. L. Hartzell, C. J. Wikstrand, G. E. Archer, J. N. Rich, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme Clin. Cancer Res., May 1, 2004; 10(9): 3216 - 3224. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() J. N. Rich, D. A. Reardon, T. Peery, J. M. Dowell, J. A. Quinn, K. L. Penne, C. J. Wikstrand, L. B. Van Duyn, J. E. Dancey, R. E. McLendon, et al. Phase II Trial of Gefitinib in Recurrent Glioblastoma J. Clin. Oncol., January 1, 2004; 22(1): 133 - 142. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() A. B. Heimberger, L. E. Crotty, G. E. Archer, K. R. Hess, C. J. Wikstrand, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson Epidermal Growth Factor Receptor VIII Peptide Vaccination Is Efficacious against Established Intracerebral Tumors Clin. Cancer Res., September 15, 2003; 9(11): 4247 - 4254. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() C. Mamot, D. C. Drummond, U. Greiser, K. Hong, D. B. Kirpotin, J. D. Marks, and J. W. Park Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells Cancer Res., June 15, 2003; 63(12): 3154 - 3161. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() A. B. Heimberger, C. A. Learn, G. E. Archer, R. E. McLendon, T. A. Chewning, F. L. Tuck, J. B. Pracyk, A. H. Friedman, H. S. Friedman, D. D. Bigner, et al. Brain Tumors in Mice Are Susceptible to Blockade of Epidermal Growth Factor Receptor (EGFR) with the Oral, Specific, EGFR-Tyrosine Kinase Inhibitor ZD1839 (Iressa) Clin. Cancer Res., November 1, 2002; 8(11): 3496 - 3502. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() G. Lammering, K. Valerie, P.-S. Lin, R. B. Mikkelsen, J. N. Contessa, J. P. Feden, J. Farnsworth, P. Dent, and R. K. Schmidt-Ullrich Radiosensitization of Malignant Glioma Cells through Overexpression of Dominant-Negative Epidermal Growth Factor Receptor Clin. Cancer Res., March 1, 2001; 7(3): 682 - 690. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() J. H. Sampson, L. E. Crotty, S. Lee, G. E. Archer, D. M. Ashley, C. J. Wikstrand, L. P. Hale, C. Small, G. Dranoff, A. H. Friedman, et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors PNAS, June 20, 2000; 97(13): 7503 - 7508. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() C. K. Tang, X.-Q. Gong, D. K. Moscatello, A. J. Wong, and M. E. Lippman Epidermal Growth Factor Receptor vIII Enhances Tumorigenicity in Human Breast Cancer Cancer Res., June 1, 2000; 60(11): 3081 - 3087. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() L. Frederick, X.-Y. Wang, G. Eley, and C. D. James Diversity and Frequency of Epidermal Growth Factor Receptor Mutations in Human Glioblastomas Cancer Res., March 1, 2000; 60(5): 1383 - 1387. [Abstract] [Full Text] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() M. Bredel, I. F. Pollack, R. L. Hamilton, and C. D. James Epidermal Growth Factor Receptor Expression and Gene Amplification in High-Grade Non-Brainstem Gliomas of Childhood Clin. Cancer Res., July 1, 1999; 5(7): 1786 - 1792. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() C.-T. Kuan, C. J. Reist, C. F. Foulon, I. A. J. Lorimer, G. Archer, C. N. Pegram, I. Pastan, M. R. Zalutsky, and D. D. Bigner 125I-labeled Anti-Epidermal Growth Factor Receptor-vIII Single-Chain Fv Exhibits Specific and High-Level Targeting of Glioma Xenografts Clin. Cancer Res., June 1, 1999; 5(6): 1539 - 1549. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() D. K. Moscatello, M. Holgado-Madruga, D. R. Emlet, R. B. Montgomery, and A. J. Wong Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor J. Biol. Chem., January 2, 1998; 273(1): 200 - 206. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() S. A. Prigent, M. Nagane, H. Lin, I. Huvar, G. R. Boss, J. R. Feramisco, W. K. Cavenee, and H.- J. S. Huang Enhanced Tumorigenic Behavior of Glioblastoma Cells Expressing a Truncated Epidermal Growth Factor Receptor Is Mediated through the Ras-Shc-Grb2 Pathway J. Biol. Chem., October 11, 1996; 271(41): 25639 - 25645. [Abstract] [Full Text] [PDF] ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() J. H. Sampson, L. E. Crotty, S. Lee, G. E. Archer, D. M. Ashley, C. J. Wikstrand, L. P. Hale, C. Small, G. Dranoff, A. H. Friedman, et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors PNAS, June 20, 2000; 97(13): 7503 - 7508. [Abstract] [Full Text] [PDF] ![]() |
![]() |
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Research | Clinical Cancer Research |
Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
Molecular Cancer Research | Cell Growth & Differentiation |